Clinical Research Directory

Inclusion Criteria: * Age ≥18 years; * Diagnosed with myelodysplastic syndrome with an IPSS-R score ≤3.5; * Requires at least 2 units of red blood cell transfusions within the 8 weeks prior to treatment; * ECOG performance status ≤2; * Willing and able to comply with the requirements for this study and written informed consent. Exclusion Criteria: * Platelet count \<50 × 10\^9/L; * Diagnosis of secondary MDS; * Previous treatment with disease-modifying agents for 4 weeks, or at least one cycle of hypomethylating agents; * History of malignant tumor within 5 years before enrollment, exclusive of cured basal or squamous cell skin cancer, superficial bladder cancer, prostate intraepithelial tumor, cervical carcinoma in situ or other indolent tumors; * Previously received organ or stem cell transplantation; * Patients with HBV, HCV, HIV or other infections that require treatment History of immunodeficiency, or congenital immunodeficiency disorders; * Any severe and/or uncontrolled medical conditions or other conditions that could affect their participation in the study, including clinically significant cardiac diseases, refractory hypertension, and other metabolic disorders prior to enrollment; * Abnormal liver function: two consecutive examinations with an interval of ≥1 week suggest that ALT and AST are 2.5 times higher than the upper limit of normal values; * Renal impairment: creatinine clearance \<60ml/min; * Having a history of mental illness or suffering from severe cerebrovascular diseases or cognitive sequelae, etc; * Received attenuated vaccine 4 in weeks before enrollment; * Participation in another clinical trial within 4 weeks before the start of this trial; * Have an allergy to luspatercept or any other part of this medicine; * Previously treated with luspatercept. Pregnant or breast-feeding patients; * Patients considered to be ineligible for the study by the investigator for reasons other than the above.